Pharmaceutical Industry Articles & Reports - Page 10

Learn how generative antibody design models like Chai-3 operate, and analyze Pfizer's licensing strategy and the pharma AI build-versus-partner decision.

Learn how Alnylam and Inceptive use generative AI foundation models for siRNA design, exploring the $2B deal structure and pharma's build-vs-partner strategy.

Learn how closed-loop generative protein engineering accelerates CNS antibody design, and evaluate the build-vs-partner R&D playbook for pharmaceutical firms.

Analyze Annual Product Quality Review (APQR) requirements comparing FDA 21 CFR 211.180(e) and EU GMP Chapter 1. Explore data trending and automation tools.

Review the FDA approval of Datroway (datopotamab deruxtecan) for first-line metastatic TNBC. Analyze TROPION-Breast02 efficacy, survival, and safety data.

Examine the architecture and adoption of Salesforce Agentforce Life Sciences. Learn how agentic CRM, headless design, and AI impact pharma commercial teams.

Analyze Sanofi's Concierge for Field, an agentic AI tool built on Snowflake Cortex and Elementum AI to automate pharma sales prep and update operating models.

Examine ASCO 2026 HARMONi-6 trial data for ivonescimab in 1L squamous NSCLC. Understand OS outcomes, PD-1xVEGF efficacy, and Summit Therapeutics US strategy.

This analysis explains the May 2026 FDA draft guidance on nonclinical safety studies for oncology biologics, single-species toxicology, and WoE approaches.

Analyze the HelioLiver AI blood test for early liver cancer detection. Examine its clinical efficacy, CRO commercialization, and MCED adoption strategies.

Analyze the integration of agentic AI systems in pharmaceutical R&D, examining Incyte's adoption of the Kosmos AI Scientist for automated drug discovery.

Analyze Bristol Myers Squibb's deployment of Anthropic Claude to 30,000 employees. Examine agentic AI enterprise strategies and pharma change management.

Examine the $10.5B Pfizer-Innovent collaboration. This analysis covers their 12-drug ADC oncology portfolio and the China cross-border licensing playbook.

Analyze the May 2026 FDA approval of Afrezza inhaled insulin for pediatric diabetes. Review INHALE-1 clinical trial data, T1D/T2D options, and market impacts.

Review the May 2026 FDA approval of Decnupaz (pivekimab sunirine), the first CD123-targeted ADC for BPDCN. Explores clinical efficacy and launch strategies.

Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.

Learn how AI pathology and deep-learning TME quantification link to postoperative ctDNA status and clinical outcomes in stage III colon cancer patients.

Analyze Google Science Skills and Gemini for Science. Understand how AlphaFold and AlphaGenome integrations impact pharma informatics and vendor evaluation.

Review the FDA accelerated approval of Hepcludex (bulevirtide) for chronic hepatitis delta virus (HDV), including clinical trial data and public health impact.

Analyze the FDA real-time AI clinical trial pilot with AstraZeneca and Amgen. Learn how cloud-based continuous monitoring impacts trial duration and workflows.

Analyze Cohere's acquisition of Reliant AI and the North for Pharma launch. Understand how agentic AI and biomedical research workbenches impact drug R&D.

Review the May 2026 FDA approval of Baxfendy (baxdrostat), analyzing its mechanism as an aldosterone synthase inhibitor for uncontrolled hypertension.

Analyze the FDA approval of Immgolis (golimumab-sldi), the first interchangeable Simponi biosimilar. Learn how auto-substitution impacts rheumatology care.

Explore the May 2026 FDA leadership shakeup, including Marty Makary's resignation. Learn how new acting directors impact drug approvals and FDA AI policy.